Table 1.
Ongoing Clinical Trials
| PARPi | Combination with | Description | Setting | Primary Endpoint | Phase | Status | NCT Identifier | ECD |
|---|---|---|---|---|---|---|---|---|
| Olaparib | Cyclophosphamide and Metformin | Safety and efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients (ENDOLA) | Recurrent | RP2D | I/II | Active, not recruiting | NCT02755844 | April, 2022 |
| Olaparib | Durvalumab | Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer (DOMEC) | Metastatic/Locally Advanced/Recurrent EC | PFS | II | Recruiting | NCT03951415 | July, 2023 |
| Olaparib | Monotherapy | UTOLA: UTerin OLAparib (UTOLA) | Advanced/Metastatic EC | PFS | II | Not yet recruiting | NCT03745950 | December, 2024 |
| Olaparib | Cediranib | Does Cediranib with Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better than Paclitaxel? (COPELIA) | Advanced/Recurrent EC | PFS | II | Recruiting | NCT03570437 | September, 2021 |
| Olaparib | Lurbinectedin | Study to evaluate PM01183 in combination with Olaparib in Advanced Solid Tumors | Advanced/Metastatic and platinum refractory EC | DLT MTD |
I/II | Unknow | NCT02684318 | October, 2019 |
| Olaparib | ATR inhibitor | ATR Inhibitor in combination with Olaparib in Gynecological Cancers with ARId1A Loss or no Loss (ATARI) | Progressive/Recurrent gynecologic cancer, included EC | ORR | II | Recruiting | NCT04065269 | March, 2023 |
| Olaparib | Vistusertib or Capivasertib | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | Advanced/Recurrent EC | MTD | I/II | Active, not recruiting | NCT02208375 | November, 2021 |
| Rucaparib | Monotherapy | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | Metastatic/Recurrent EC | PFS | II | Recruiting | NCT03617679 | September, 2022 |
| Rucaparib | Nivolumab | Rucaparib and Nivolumab in Patients with prostate or endometrial cancer | Metastatic EC | DLT | I/II | Recruiting | NCT03572478 | December, 2021 |
| Rucaparib | Bevacizumab and Atezolizumab | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (ENDOBARR) | Recurrent/Persistent EC | ORR | II | Recruiting | NCT03694262 | June, 2026 |
| Rucaparib | Bevacizumab | Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium (Clovis-001) | Persistent/Recurrent EC | PFS | II | Active, not recruiting | NCT03476798 | February, 2023 |
| Rucaparib | Mirvetuximab Soravtansine | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Recurrent EC | RPTD | I | Recruiting | NCT03552471 | August, 2021 |
| Niraparib | Dostarlimab or Alone | Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer | Recurrent EC | CBR | II | Recruiting | NCT03016338 | December, 2023 |
| Niraparib | Monotherapy | Trial of Maintenance with Niraparib-Uterine Serous Carcinoma | Advanced, platinum-sensitive USC | PFS | II | Recruiting | NCT04080284 | July, 2025 |
| Niraparib | Copansilib | Niraparib and Copansilib in treating patients with Recurrent Endometrial, Ovarian, Primary peritoneal, or Fallopian Tube Cancer | Recurrent EC | MTD | I | Recruiting | NCT03586661 | April, 2022 |
| Talazoparib | Avelumab | Avelumab in Patients with MSS, MSI-H and POLE-Mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib in Patient with MSS Recurrent or Persistent Endometrial Cancer | Recurrent/Persistent EC | PFS6 | II | Recruiting | NCT02912572 | April, 2024 |
| Talazoparib | Monotherapy | A Parp Inhibitor (BMN 673) for Inoperable Advanced Endometrial Cancer (PANDA) | Inoperable, advanced EC | PFS | II | Withdrawn | NCT02127151 | October, 2018 |
| Talazoparib | Radiotherapy | Talazoparib and Radiation Therapy in Treating Patients with Locally Recurrent Gynecologic Cancers | Advanced/Recurrent gynecologic cancer, included EC | MTD DLT |
I | Recruiting | NCT03968406 | October, 2021 |
Abbreviations: EC, endometrial cancer; MTD, maximum tolerated dose; MSI-H, microsatellite instable-hypermutated; MSS, microsatellite stable; DLT, dose-limiting toxicities; RP2D, recommended Phase II trial dose; ORR, overall response rate; PFS, progression-free survival; CBR, clinical benefit rate.